The CDK4/6 inhibitor palbociclib, which is approved for the treatment of breast cancer, demonstrated potent anti‐proliferative activity and differentiation induction in murine AML cells driven by NUP98::KDM5A, NUP98::DDX10, and NUP98::NSD1, as well as in human NUP98‐r leukemic cells.135. Here, KDM5A is linked to acute myeloid leukemia.